Pharmacokinetic analysis of in vivo disposition of heparin-superoxide dismutase

Biomedicine and Pharmacotherapy

Volumn 64, Issue 10, 2010, Pages 686-691

  Liu, J ^a,b   Zhao, T ^a   Tan, H ^a   Cheng, Y ^a   Cao, J ^a   Wang, F ^a  

^a SHANDONG UNIVERSITY   (China)

^b QUFU NORMAL UNIVERSITY   (China)

Author keywords

Cu,Zn superoxide dismutase; Heparin superoxide dismutase; Pharmacokinetics

Indexed keywords

HEPARIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

ANIMALS; CIRCULAR DICHROISM; HALF-LIFE; HEPARIN; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, JIMPY; PROTEIN STRUCTURE, SECONDARY; RATS; REACTIVE OXYGEN SPECIES; SPECTROPHOTOMETRY, ULTRAVIOLET; SUPEROXIDE DISMUTASE; TISSUE DISTRIBUTION;

EID: 78649830463     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.09.008     Document Type: Article

References (40)

1. Mihara K., Oka Y., Sawai K., Takakura Y., Hashida M. Improvement of therapeutic effect of human recombinant superoxide dismutase on ischemic acute renal failure in the rat via cationization and conjugation with polyethylene glycol. J Drug Target 1994, 2(4):317-321.
2. Yabe Y., Nishikawa M., Tamada A., Takakura Y., Hashida M. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. J Pharmacol Exp Ther 1999, 289(2):1176-1184.
3. Yabe Y., Kobayashi N., Nishihashi T., Takahashi R., Nishikawa M., Takakura Y., et al. Prevention of neutrophil-mediated hepatic ischemia/reperfusion injury by superoxide dismutase and catalase derivatives. J Pharmacol Exp Ther 2001, 298(3):894-899.
4. Bellocq A., Azoulay E., Marullo S., Flahault A., Fouqueray B., Philippe C., et al. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol 1999, 21(1):128-136.
5. Hagimoto N., Kuwano K., Inoshima I., Yoshimi M., Nakamura N., Fujita M., et al. TGF-beta 1 as an enhancer of Fas-mediated apoptosis of lung epithelial cells. J Immunol 2002, 168(12):6470-6478.
6. Cuzzocrea S., Thiemermann C., Salvemini D. Potential therapeutic effect of antioxidant therapy in shock and inflammation. Curr Med Chem 2004, 11(9):1147-1162.
7. Kinnula V.L., Crapo J.D. Superoxide dismutases in the lung and human lung diseases. Am J Respir Crit Care Med 2003, 167(12):1600-1619.
8. Landis G.N., Tower J. Superoxide dismutase evolution and life span regulation. Mech Ageing Dev 2005, 126(3):365-379.
9. Fujita T., Furitsu H., Nishikawa M., Takakura Y., Sezaki H., Hashida M. Therapeutic effects of superoxide dismutase derivatives modified with mono- or polysaccharides on hepatic injury induced by ischemia/reperfusion. Biochem Biophys Res Commun 1992, 189(1):191-196.
10. Tsubokawa T., Jadhav V., Solaroglu I., Shiokawa Y., Konishi Y., Zhang J.H. Lecithinized superoxide dismutase improves outcomes and attenuates focal cerebral ischemic injury via antiapoptotic mechanisms in rats. Stroke 2007, 38(3):1057-1062.
11. Bayati A., Källskog O., Odlind B., Wolgast M. Plasma elimination kinetics and renal handling of copper/zinc superoxide dismutase in the rat. Acta Physiol Scand 1988, 134(1):65-74.
12. Swart P.J., Hirano T., Kuipers M.E., Ito Y., Smit C., Hashida M., et al. Targeting of superoxide dismutase to the liver results in anti-inflammatory effects in rats with fibrotic livers. J Hepatol 1999, 31(6):1034-1043.
13. Rubinstein A., Kakunda A., Kohen R. Protection of the rat jejunal mucosa against oxidative injury by cationized superoxide dismutase. J Pharm Sci 1993, 82(12):1285-1287.
14. Blau S., Kohen R., Bass P., Rubinstein A. The effect of local attachment of cationized antioxidant enzymes on experimental colitis in the rat. Pharm Res 2000, 17(9):1077-1084.
15. Mihara K., Sawai K., Takakura Y., Hashida M. Manipulation of renal disposition of human recombinant superoxide dismutase by chemical modification. Biol Pharm Bull 1994, 17(2):296-301.
16. Qi J.Z., Wang F.S., Zhang H.W., Cao J.C., Zhang T.M. Chemical Modification of Superoxide Disnmtase by Low Molecular Weight Heparin and Their Physical and Chemical Properties. Chin Pharm J 2006, 41:150-153.
17. Zhang H.W., Wang F.S., Shao W., Zheng X.L., Qi J.Z., Cao J.C., et al. Stability Investigation of Cu,Zn-Superoxide Dismutase Covalently Modified by Low Molecular Weight Heparin. Biochemistry &LPKT;Moscow&RPKT; 2006, 71:S96-100.
18. Liu J., Wang X., Wang F., Teng L., Cao J. Attenuation effects of heparin-superoxide dismutase conjugate on bleomycin-induced lung fibrosis in vivo and radiation-induced inflammatory cytokine expression in vitro. Biomed Pharmacother 2009, 63(7):484-491.
19. Liu J., Tan H., Sun Y., Zhou S., Cao J., Wang F. The preventive effects of heparin-superoxide dismutase on carbon tetrachloride-induced acute liver failure and hepatic fibrosis in mice. Mol Cell Biochem 2009, 327:219-228.
20. Liu J., Teng L., Liu C., Hu L., Wang Y., Liu H., et al. Argument delivery of superoxide dismutase to macrophages by chemical modification with polysaccharide and attenuation effects on radiation-induced inflammatory cytokine expression in vitro. J Drug Target 2009, 17(3):216-224.
21. Qi J., Li Y., Zhang H., Cheng Y., Sun Y., Cao J., et al. A novel conjugate of low-molecular-weight heparin and Cu,Zn-superoxide dismutase: Study on its mechanism in preventing brain reperfusion injury after ischemia in gerbils. Brain Research 2009, 1260:76-83.
22. Habeeb A.F. Determination of free amino groups in proteins by trinitrobenzenesulfonic acid. Anal Biochem 1966, 14(3):328-336.
23. Ma S.F., Nishikawa M., Katsumi H., Yamashita F., Hashida M. Liver targeting of catalase by cationization for prevention of acute liver failure in mice. J Control Release 2006, 110(2):273-282.
24. Takagi T., Kitano M., Masuda S., Tokuda H., Takakura Y., Hashida M. Augmented inhibitory effect of superoxide dismutase on superoxide anion release from macrophages by direct cationization. Biochim Biophys Acta 1997, 1335(1-2):91-98.
25. Yang X.X., Hu Z.P., Chan E., Duan W., Zhou S. Pharmacokinetics of recombinant human endostatin in rats. Curr Drug Metab 2006, 7(6):565-576.
26. Sönmez K., Demiroǧullari B., Türkyilmaz Z., Sancak B., Karabulut R., Kale N., et al. Effects of polyethyleneglycol-superoxide dismutase &LPKT;PEG-SOD&RPKT; and pentoxifylline on small intestinal anastomoses established in the 24th hour of reperfusion: an experimental study in rats. Res Commun Mol Pathol Pharmacol 2001, 110(1-2):97-106.
27. Prentice E.D., Antonson D.L., Leibrock L.G., Prabhu V.C., Kelso T.K., Sears T.D. An update on the PEG-SOD study involving incompetent subjects: FDA permits an exception to informed consent requirements. IRB 1994, 16(1-2):16-18.
28. Bussey H., Francis J.L. Heparin overview and issues. Pharmacotherapy 2004, 24:103S-107S.
29. Tyrrell D.J., Horne A.P., Holme K.R., Preuss J.M., Page C.P. Heparin in inflammation: potential therapeutic applications beyond anticoagulation. Adv Pharmacol 1999, 46:151-208.
30. Rose M.J., Page C. Glycosaminoglycans and the regulation of allergic inflammation. Curr Drug Targets Inflamm Allergy 2004, 3:221-225.
31. Tyagi S.C., Kumar S., Katwa L. Differential regulation of extracellular matrix metalloproteinase and tissue inhibitor by heparin and cholesterol in fibroblast cells. J Mol Cell Cardiol 1997, 29(1):391-404.
32. Asselot-Chapel C., Combacau L., Labat-Robert J., Kern P. Expression of fibronectin and interstitial collagen genes in smooth muscle cells: modulation by low molecular weight heparin fragments and serum. Biochem Pharmacol 1995, 49(5):653-659.
33. el Nabout R., Martin M., Remy J., Robert L., Lafuma C. Heparin fragments modulate the collagen phenotype of fibroblasts from radiation-induced subcutaneous fibrosis. Exp Mol Pathol 1989, 51(2):111-122.
34. Castellot J.J., Wong K., Herman B., Hoover R.L., Albertini D.F., Wright T.C., et al. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol 1985, 124(1):13-20.
35. Adachi T., Hara H., Yamada H., Yamazaki N., Yamamoto M., Sugiyama T., et al. Heparin-stimulated expression of extracellular-superoxide dismutase in human fibroblasts. Atherosclerosis 2001, 159(2):307-312.
36. Zhang Z.G., Zhang Q.Z., Cheng Y.N., Ji S.L., Du G.H. Antagonistic effects of ultra-low-molecular-weight heparin against cerebral ischemia/reperfusion injury in rats. Pharmacol Res 2007, 56(4):350-355.
37. Park K., Kim Y.S., Lee G.Y., Park R.W., Kim I.S., Kim S.Y., et al. Tumor endothelial cell targeted cyclic RGD-modified heparin derivative: inhibition of angiogenesis and tumor growth. Pharm Res 2008, 25(12):2786-2798.
38. Presta M., Leali D., Stabile H., Ronca R., Camozzi M., Coco L., et al. Heparin derivatives as angiogenesis inhibitors. Curr Pharm Des 2003, 9(7):553-566.
39. Peiser L., Gordon S. The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect 2001, 3(2):149-159.
40. Yamasaki Y., Hisazumi J., Yamaoka K., Takakura Y. Efficient scavenger receptor-mediated hepatic targeting of proteins by introduction of negative charges on the proteins by aconitylation: the influence of charge density and size of the proteins molecules. Eur J Pharm Sci 2003, 18(5):305-312.